CareDx
Clinical trials sponsored by CareDx, explained in plain language.
CareDx
CDNA
NASDAQ
Diagnostics company specializing in transplant monitoring tests.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New blood test could spot cancer return after transplant Results expected Oct 2026 (estimated)
- New registry monitors heart transplant patients for better rejection detection Results expected Nov 2026 (estimated)